首页 / 产品中心 / 单克隆抗体 /

货号: YP-rAb-17813
促销价:

产品介绍

反应种属
Human,Mouse,Rat
应用范围
WB,IHC,IF,IP,ELISA
抗体类型
单克隆抗体
基因名称(Gene Name)
JAK2
蛋白名称
JAK2
分子量(DA)
131kD
免疫原
特异性
Endogenous
组成
PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
来源
Monoclonal, Rabbit,IgG
稀释比例
IHC 1:200-1:1000; WB 1:2000-1:10000; IF 1:200-1:1000; ELISA 1:5000-1:20000; IP 1:50-1:200; Note: For IHC, we suggest antigen retrieval with TE buffer pH 9.0
纯化工艺
Protein A
浓度
0.5 mg/ml
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
其他名称
JAK2;Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2)
背景
This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq, Jul 2008],
功能
Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,Disease:Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.,Disease:Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.,Disease:Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites.,Disease:Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.,Disease:Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients.,Disease:Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.,Domain:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.,Function:Plays a role in leptin signaling and control of body weight (By similarity). Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.,PTM:Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.,similarity:Contains 1 FERM domain.,similarity:Contains 1 protein kinase domain.,similarity:Contains 1 SH2 domain.,subcellular location:Wholly intracellular, possibly membrane associated.,subunit:Interacts with SIRPA and SH2B1 (By similarity). Interacts with IL23R, SKB1 and STAM2.,tissue specificity:Expressed in blood, bone marrow and lymph node.,

展开

产品详情

客户数据及评论 (0)

折叠内容

文献引用

折叠内容

优品生物的抗体,可以回收利用几次?

首先,一般抗体不推荐客户回收利用,抗体使用之后缓冲体系已经发生改变,不同客户在回收抗体的保存条件上也会有差异,所以抗体回收使用效果无法保证。另外,优品生物也做过一批抗体回收验证测试,测试结果显示不同抗体可回收次数不同,一般效价越高的抗体,可重复使用的次数越多,客户可根据实验情况来确定。
注:我们将孵育完毕后剩余的抗体回收到离心管中置于4℃保存,效价高的抗体可至少保存1周,至少重复利用3次。

收起

优品生物作为国产抗体品牌的优势?

优品生物是国产品牌,通过聚焦抗体与酶核心技术,致力于打破国际技术的垄断,我们拥有包括兔多克隆抗体、小鼠单克隆抗体、兔单克隆抗体的生产研发平台,同时也有包括WB,IP在内的检测平台,我们对每一支自产的抗体进行了严格的检测。当然,我们部分直销地区也可以帮客户代购进口品牌的产品。同时也有抗体定制服务。优品生物l抗体优势:1,严自检,保质量;2产品多,指标全;3,价格低,货期短。

收起

优品生物抗体成分?

优品生物抗体成分在平时工作当中,常会有客户咨询我们的抗体用的什么buffer进行保存,一般来说,我们的buffer的成分是:PBS含0.03%的proclin300、0.05%牛血清白蛋白、50%甘油;也有一些是PBS含0.03%的proclin300,50%甘油。防腐剂 Proclin 300活性成分主要是2-甲基-4-异噻唑啉-3-酮(MCI)和5-氯-2-甲基-4-异噻唑啉-3-酮(CMCI)。ProClin生物灭活剂能够迅速穿透细胞膜,抑制对细胞呼吸至关重要的特定酶,因此一接触微生物有机体就会立即抑制细胞活性。ProClin的多个特定毒性位点可以防止微生物产生高水平的耐药性。

收起

实验方案

折叠内容
>